Baptist Memorial Hospital - Golden Triangle INC.
Baptist Memorial Hospital - Golden Triangle INC. was paid $56.02M by Medicaid between Jan 2018 and Dec 2024, across 366 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
COLUMBUS, MS 39705
Next to other Ambulance providers in Mississippi
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 240,350 | $7.89M | |
| 2019 | 243,024 | $8.44M | |
| 2020 | 214,503 | $6.63M | |
| 2021 | 285,422 | $7.78M | |
| 2022 | 322,493 | $8.64M | |
| 2023 | 287,011 | $9.55M | |
| 2024incomplete | 224,240 | $7.09M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 53,084 | 41,636 | $8.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 50,758 | 41,554 | $6.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 31,300 | 23,972 | $5.25M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 27,086 | 19,553 | $1.90M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.1% | 48,168 | 34,488 | $1.75M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 2.6% | 12,871 | 8,322 | $1.46M |
| A0425 | Ground mileage, per statute mile | 2.3% | 18,638 | 11,492 | $1.28M |
| G0378 | Hospital observation service, per hour | 2.2% | 3,481 | 2,316 | $1.26M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 15,178 | 13,043 | $1.23M |
| 71045 | Radiologic examination, chest; single view | 2.1% | 32,061 | 24,378 | $1.16M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 9,376 | 7,285 | $1.12M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.8% | 10,734 | 7,537 | $1.04M |
354 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.8% | 9,001 | $991K |
| A0427 | Emergency ambulance ride, advanced life support | 1.7% | 10,835 | $945K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.3% | 212 | $705K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 29,033 | $679K |
| J0897 | Injection, denosumab, 1 mg | 1.2% | 1,603 | $664K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 9,173 | $644K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 13,125 | $634K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,279 | $628K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 53,612 | $607K |
| 80053 | Comprehensive metabolic panel | 1.1% | 96,800 | $590K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 16,770 | $588K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,890 | $526K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16,483 | $507K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,413 | $462K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 100,754 | $435K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,738 | $418K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16,953 | $413K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 717 | $403K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,664 | $399K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,774 | $395K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,264 | $363K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,883 | $340K |
| 93458 | <1% | 384 | $335K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,367 | $327K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23,337 | $325K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,788 | $318K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,897 | $284K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,339 | $274K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,642 | $271K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 142 | $262K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 853 | $260K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,201 | $256K |
| 36415 | Collection of venous blood by venipuncture | <1% | 118,948 | $248K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,791 | $235K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 725 | $231K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 9,887 | $214K |
| D0272 | Bitewings - two radiographic images | <1% | 352 | $208K |
| 36902 | <1% | 214 | $196K | |
| 86900 | <1% | 4,788 | $194K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,691 | $193K |
| 36430 | <1% | 1,972 | $180K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,218 | $172K |
| 84484 | <1% | 23,772 | $158K | |
| 76801 | <1% | 2,034 | $137K | |
| 72100 | <1% | 2,963 | $132K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,267 | $132K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,412 | $131K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,931 | $127K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,936 | $120K |
| 73560 | <1% | 3,472 | $117K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,018 | $117K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,737 | $112K |
| 81001 | <1% | 47,760 | $106K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,811 | $106K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15,594 | $95K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,314 | $93K |
| 83735 | <1% | 25,915 | $87K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,663 | $85K |
| 83880 | <1% | 4,562 | $84K | |
| 94726 | <1% | 1,193 | $79K | |
| 73630 | <1% | 2,032 | $78K | |
| 36600 | <1% | 3,038 | $78K | |
| 86850 | <1% | 4,139 | $77K | |
| 73610 | <1% | 1,868 | $77K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,190 | $76K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,365 | $76K |
| 73030 | <1% | 2,271 | $75K | |
| 74018 | <1% | 1,669 | $73K | |
| 47562 | <1% | 30 | $73K | |
| 85027 | <1% | 19,157 | $72K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 28,093 | $72K |
| 93017 | <1% | 1,202 | $72K | |
| 93971 | <1% | 2,107 | $71K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,138 | $71K |
| 87807 | <1% | 6,937 | $71K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,394 | $70K |
| 95811 | <1% | 209 | $69K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 203 | $69K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,371 | $67K |
| 96367 | <1% | 2,710 | $66K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,854 | $65K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,855 | $65K |
| 83690 | <1% | 15,104 | $63K | |
| 73130 | <1% | 1,572 | $59K | |
| 86901 | <1% | 4,788 | $58K | |
| A0380 | Bls mileage (per mile) | <1% | 135 | $57K |
| 71250 | <1% | 1,821 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,373 | $54K |
| 86923 | <1% | 1,464 | $51K | |
| 80061 | Lipid panel | <1% | 5,878 | $50K |
| 83605 | <1% | 9,319 | $50K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,483 | $49K |
| 87040 | <1% | 8,462 | $46K | |
| 81025 | <1% | 8,143 | $44K | |
| 82803 | <1% | 3,079 | $42K | |
| 73502 | <1% | 1,532 | $42K | |
| 94060 | <1% | 481 | $41K | |
| 93798 | <1% | 1,819 | $40K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 4,174 | $40K |
| 96417 | <1% | 1,509 | $40K | |
| 84702 | <1% | 3,848 | $40K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 791 | $38K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 29 | $38K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 576 | $36K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,643 | $36K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 509 | $36K |
| 86300 | <1% | 4,658 | $35K | |
| 82728 | <1% | 6,241 | $34K | |
| 10060 | <1% | 372 | $34K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,090 | $33K |
| 97161 | <1% | 1,084 | $32K | |
| 73110 | <1% | 818 | $31K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,892 | $30K |
| 72040 | <1% | 899 | $30K | |
| 77300 | <1% | 100 | $29K | |
| A9270 | Non-covered item or service | <1% | 12,804 | $28K |
| 96523 | <1% | 1,535 | $28K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 223 | $27K |
| 84703 | <1% | 5,105 | $26K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,662 | $26K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 307 | $26K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,476 | $25K |
| 93925 | <1% | 436 | $24K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,241 | $23K |
| 82375 | <1% | 2,905 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 372 | $20K |
| 85007 | <1% | 8,081 | $20K | |
| 85610 | <1% | 8,711 | $20K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 183 | $19K |
| 96411 | <1% | 779 | $18K | |
| 70486 | <1% | 403 | $18K | |
| 82150 | <1% | 3,811 | $18K | |
| 83550 | <1% | 5,537 | $16K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 899 | $16K |
| 84439 | <1% | 3,411 | $16K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 437 | $15K |
| 82607 | <1% | 2,370 | $15K | |
| 85379 | <1% | 2,729 | $15K | |
| 77336 | <1% | 248 | $14K | |
| 86140 | <1% | 4,934 | $14K | |
| 97116 | <1% | 1,276 | $13K | |
| 70491 | <1% | 187 | $13K | |
| 83050 | <1% | 2,893 | $13K | |
| 83540 | <1% | 5,550 | $12K | |
| 87070 | <1% | 2,235 | $12K | |
| 93970 | <1% | 189 | $12K | |
| 82378 | <1% | 2,019 | $12K | |
| 85730 | <1% | 3,060 | $10K | |
| 80069 | <1% | 3,041 | $10K | |
| 93922 | <1% | 259 | $10K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 64 | $9K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 196 | $9K |
| 75716 | <1% | 14 | $9K | |
| 74178 | <1% | 84 | $8K | |
| 83615 | <1% | 2,634 | $7K | |
| 93880 | <1% | 132 | $7K | |
| 82550 | <1% | 2,093 | $7K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 39 | $7K |
| 82746 | <1% | 1,306 | $7K | |
| 73140 | <1% | 167 | $6K | |
| 87205 | <1% | 2,271 | $6K | |
| 84550 | <1% | 2,325 | $6K | |
| 82570 | <1% | 2,074 | $6K | |
| 85045 | <1% | 2,969 | $6K | |
| 85652 | <1% | 4,132 | $6K | |
| 73080 | <1% | 152 | $6K | |
| 76000 | <1% | 39 | $5K | |
| 70498 | <1% | 138 | $5K | |
| 72131 | <1% | 158 | $5K | |
| 82784 | <1% | 2,535 | $5K | |
| 82565 | <1% | 2,395 | $5K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 271 | $5K |
| 84153 | <1% | 926 | $5K | |
| 73590 | <1% | 112 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 447 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 298 | $5K |
| 80164 | <1% | 544 | $4K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 889 | $4K |
| 80074 | <1% | 231 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 24,541 | $4K |
| 97162 | <1% | 111 | $4K | |
| 87210 | <1% | 1,129 | $4K | |
| 82043 | <1% | 1,145 | $4K | |
| 72070 | <1% | 59 | $4K | |
| 94010 | <1% | 66 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 257 | $3K |
| 83883 | <1% | 1,005 | $3K | |
| 76642 | <1% | 86 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 74 | $3K |
| 78227 | <1% | 13 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,311 | $3K |
| D1120 | Dental cleaning, child | <1% | 395 | $3K |
| 70496 | <1% | 64 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,232 | $3K |
| 12001 | <1% | 28 | $3K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 68 | $3K |
| 84165 | <1% | 1,125 | $2K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 25 | $2K |
| 92523 | <1% | 32 | $2K | |
| 73090 | <1% | 64 | $2K | |
| 76775 | <1% | 52 | $2K | |
| D1206 | Topical application of fluoride varnish | <1% | 357 | $2K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $2K |
| 90686 | <1% | 284 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,850 | $2K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,182 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 55 | $2K |
| 36589 | <1% | 13 | $2K | |
| 36416 | <1% | 695 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,258 | $1K |
| 96415 | <1% | 32 | $1K | |
| 84156 | <1% | 590 | $1K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 17 | $1K |
| 86803 | <1% | 167 | $1K | |
| 96416 | <1% | 20 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,752 | $1K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 21 | $1K |
| 76770 | <1% | 15 | $1K | |
| 83970 | <1% | 60 | $1K | |
| 74019 | <1% | 13 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12,431 | $1K |
| 84480 | <1% | 90 | $997.36 | |
| 86003 | <1% | 623 | $951.52 | |
| 84100 | <1% | 500 | $947.71 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 712 | $930.30 |
| 82009 | <1% | 407 | $929.98 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 280 | $913.59 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 173 | $846.69 |
| 36591 | <1% | 391 | $716.38 | |
| 80177 | <1% | 76 | $667.12 | |
| 83516 | <1% | 186 | $663.78 | |
| C1769 | Guide wire | <1% | 4,563 | $660.49 |
| 86480 | <1% | 31 | $631.02 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,187 | $608.12 |
| 76536 | <1% | 13 | $598.58 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,720 | $591.07 |
| 74022 | <1% | 15 | $580.97 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,128 | $579.23 |
| 85014 | <1% | 321 | $554.97 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $529.71 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,298 | $508.27 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 190 | $484.76 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 8,769 | $474.89 |
| 86038 | <1% | 90 | $464.82 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,830 | $459.62 |
| 96377 | <1% | 111 | $454.56 | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 832 | $433.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,373 | $410.22 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 212 | $399.05 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,638 | $388.22 |
| 0012A | <1% | 17 | $387.65 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 326 | $358.18 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13,508 | $350.63 |
| 85018 | <1% | 220 | $350.02 | |
| 96376 | <1% | 5,314 | $340.35 | |
| 0004A | <1% | 16 | $335.13 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 29 | $313.81 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,917 | $305.24 |
| 82785 | <1% | 29 | $290.84 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 920 | $288.95 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,933 | $275.80 |
| 83695 | <1% | 54 | $271.73 | |
| 82272 | <1% | 99 | $266.83 | |
| 0011A | <1% | 25 | $259.94 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,930 | $257.52 |
| 82085 | <1% | 56 | $237.94 | |
| 87046 | <1% | 12 | $219.88 | |
| 87427 | <1% | 18 | $218.96 | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 400 | $217.14 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 254 | $209.86 |
| 85384 | <1% | 34 | $195.10 | |
| 80076 | <1% | 31 | $189.35 | |
| 84681 | <1% | 16 | $179.85 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 504 | $178.66 |
| 83655 | <1% | 13 | $175.76 | |
| 82553 | <1% | 23 | $173.77 | |
| 86200 | <1% | 25 | $140.52 | |
| 86160 | <1% | 26 | $130.48 | |
| 85347 | <1% | 38 | $120.28 | |
| 87045 | <1% | 12 | $114.69 | |
| 83525 | <1% | 14 | $98.81 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,295 | $93.08 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 409 | $92.98 |
| 86060 | <1% | 12 | $89.93 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,179 | $82.70 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 13 | $82.68 |
| 86308 | <1% | 17 | $62.60 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 992 | $53.53 |
| 84132 | <1% | 13 | $50.09 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,067 | $49.32 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,594 | $44.15 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,034 | $36.84 |
| J2704 | Injection, propofol, 10 mg | <1% | 7,006 | $33.32 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,141 | $23.30 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,814 | $22.95 |
| 83521 | <1% | 1,131 | $22.18 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,640 | $15.97 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,764 | $12.80 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,525 | $12.28 |
| 94729 | <1% | 1,205 | $11.79 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,350 | $10.50 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,020 | $8.94 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 89 | $7.86 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,290 | $6.76 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 243 | $6.03 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 556 | $4.07 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 15 | $1.91 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 283 | $1.71 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 50 | $0.89 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,974 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 1,263 | $0.00 |
| 94760 | 0% | 230 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 507 | $0.00 |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | 0% | 675 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 76 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,433 | $0.00 |
| 36410 | 0% | 13 | $0.00 | |
| 96368 | 0% | 662 | $0.00 | |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | 0% | 2,864 | $0.00 |
| 77001 | 0% | 428 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 946 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 941 | $0.00 |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 0% | 207 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 343 | $0.00 |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 0% | 81 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 31 | $0.00 |
| J2805 | Injection, sincalide, 5 micrograms | 0% | 12 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 733 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 413 | $0.00 |
| J3490 | Unclassified drugs | 0% | 125 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 30 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 27 | $0.00 |
| 99205 | Prolong outpt/office vis | 0% | 16 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 33 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 853 | $0.00 |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 33 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 451 | $0.00 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0% | 282 | $0.00 |
| 90715 | 0% | 629 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 901 | $0.00 |
| 84145 | 0% | 640 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 476 | $0.00 |
| 76937 | 0% | 415 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 563 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 65 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 67 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 128 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 59 | $0.00 |
| C1729 | Catheter, drainage | 0% | 40 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 102 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 13 | $0.00 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 128 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 21 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.